Citations

Clear

3057 citation(s) found for "Cd, Johnson".

P1‐173: A kindred with familial frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72
Wicklund, Meredith, Daube, Jasper R., DeJesus‐Hernandez, Mariely, Parisi, Joseph E. , Josephs, Keith A. , Kuntz, Karen M. , Johnson, Kris , Ivnik, Robert J., Petersen, Ronald C. , Rademachers, Rosa, Boeve, Bradley F. , Dickson, Dennis W. , Baker, Matthew , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | July 19, 2012 | Volume: 8 | Issue: 4S_Part_5 | Pages: No page available

10.1016/j.jalz.2012.05.451 Get It

Videoscopic Left Cardiac Sympathetic Denervation for Patients With Recurrent Ventricular Fibrillation/Malignant Ventricular Arrhythmia Syndromes Besides Congenital Long-QT Syndrome
Coleman, Mira A., Bos, J. Martijn , Johnson, Jonathan N. , Owen, Heidi J., Deschamps, Claude, Moir, Christopher R. , Ackerman, Michael J. , Bos, Johan M

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 12, 2012 | Volume: 5 | Issue: 4 | Pages: 782-788

10.1161/circep.112.971754 | PMID 22787014 Get It

Background— Treatment options for patients with recurrent ventricular arrhythmias refractory to pharmacotherapy and ablation are minimal. Although left cardiac sympathetic denervation (LCSD) is well established in long-QT syndrome, its role in non–long-QT syndrome arrhythmogenic channelopathies and cardiomyopathies is less clear. Here, we report our single-center experience in performing LCSD in this setting. Methods and Results— In this institutional review board–approved study, we retrospectively reviewed the electronic medical records of all patients (N=91) who had videoscopic LCSD at our institution from 2005 to 2011. Data were analyzed for the subset (n=27) who were denervated for an underlying diagnosis other than autosomal dominant or sporadic long-QT syndrome. The spectrum of arrhythmogenic disease included catecholaminergic polymorphic ventricular tachycardia (n=13), Jervell and Lange-Nielsen syndrome (n=5), idiopathic ventricular fibrillation (n=4), left ventricular noncompaction (n=2), hypertrophic cardiomyopathy (n=1), ischemic cardiomyopathy (n=1), and arrhythmogenic right ventricular cardiomyopathy (n=1). Five patients had LCSD because of high-risk assessment and β-blocker intolerance, none of whom had a sentinel breakthrough cardiac event at early follow-up. Among the remaining 22 previously symptomatic patients who had LCSD as secondary prevention, all had an attenuation in cardiac events, with 18 having no breakthrough cardiac events so far and 4 having experienced ≥1 post-LCSD breakthrough cardiac event. Conclusions— LCSD may represent a substrate-independent antifibrillatory treatment option for patients with life-threatening ventricular arrhythmia syndromes other than long-QT syndrome. The early follow-up seems promising, with a marked reduction in the frequency of cardiac events postdenervation.